98%
921
2 minutes
20
Objective: Trials testing promising interventions in knee osteoarthritis (OA) often fail to show pain reductions. This may be due to change in activity whereby a person's pain decreases, leading them to increase their activity levels, in turn increasing pain back to baseline levels. Using data from a trial of a beneficial treatment for knee pain, we explored whether activity changes might mask a treatment's effect on pain, by looking at whether activity levels increased with effective treatment and whether change in activity level related to change in pain.
Design: During the InRespond trial (ISRCTN55059760) participants wore an accelerometer for 7 days before and during treatments. We assessed change in pain on treatment using scores for overall knee pain and pain in a nominated pain-aggravating activity both in the last week and evaluated change in different types of activity using accelerometer data. Principal components analysis tested whether change in activity and pain outcomes were correlated and created composites combining them. We then tested whether activity, pain or the composites showed a treatment effect, and examined their responsiveness.
Results: In the 61 participants (mean age 64.5 years, 38% women, mean overall knee pain score 5.08 (0-10)), activity levels mostly decreased during the trial. Principal component analyses suggested that pain and activity did not correlate highly, loading on different components. Treatment that showed significant effects on pain did not show similar effects on either activity (e.g. the active treatment had a slightly greater reduction in total steps taken than the control treatment (difference 1942.6 steps/week, p = 0.42) nor on composites combining activity and pain. Pain outcomes were the most responsive; static loading (standing) outcomes were the most responsive activity outcome.
Conclusion: We found no evidence to support the hypothesis that activity levels increase during effective OA treatment and might account for the negligible pain effects of OA treatments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718134 | PMC |
http://dx.doi.org/10.1016/j.ocarto.2020.100063 | DOI Listing |
JPEN J Parenter Enteral Nutr
September 2025
Center for Sarcopenia and Malnutrition Research, Kumamoto Rehabilitation Hospital, Kumamoto, Japan.
Background: Limited evidence exists regarding the cognitive and physical improvement effects of medium-chain triglyceride (MCT) intake in patients with stroke. This study aimed to investigate the association between MCT-enhanced rice consumption and enhancements in outcomes, including cognitive level, in patients following stroke.
Methods: We performed a retrospective cohort study on adults admitted to a rehabilitation center with cognitive decline following acute stroke.
J Sep Sci
September 2025
Programa De Pós-Graduação em Química, Universidade Federal de Sergipe, São Cristóvão, Sergipe, Brazil.
Secondary metabolites are important bioactive compounds for diet and medicine. This study optimizes the extraction of hydroethanolic herbal extracts using an EDGE (Energized Dispersive Guided Extraction) system, evaluates their antioxidant capacity, and analyzes correlations among antioxidant activity, total phenolic content, and individual compounds. A Doehlert matrix design was used to optimize extraction, having temperature and time as independent variables, and total phenolic content (mg GAE/g) as the response, quantified via the Folin-Ciocalteu method.
View Article and Find Full Text PDFPlant Dis
September 2025
Shenyang Agricultural University, College of Plant Protection, Nematology Institute of Northern China, Shenyang, China;
Root-knot nematodes (Meloidogyne spp.) cause catastrophic yield losses in global agriculture. This study identified itaconic acid (IA), through comparative metabolomic analysis (the study of small molecules in biological systems), as a key virulence-related metabolite produced by the fungus Trichoderma citrinoviride Snef1910.
View Article and Find Full Text PDFBiomed Chromatogr
October 2025
Department of Rehabilitation, Nan'ao People's Hospital, Shenzhen, China.
Chrysotobibenzyl, a bioactive ingredient from Dendrobium chrysotoxum, exhibits potent anti-tumor activity. However, its metabolic profiles remain unelucidated. This study aimed to disclose the metabolic fates of chrysotobibenzyl using human liver fractions.
View Article and Find Full Text PDFBMC Med Educ
September 2025
Medical Didactics and Education Research, DEMEDA, Faculty of Medicine, University of Augsburg, Augsburg, Germany.